Allergan acknowledges revised, unsolicited proposal from Valeant and Pershing Square

02-06-2014 Business Wire HealthComments (0)

AllerganBiotechnologyPharmaceuticalUSAValeant Pharmaceuticals

Allergan (NYSE: AGN) today acknowledged that Valeant Pharmaceuticals International and Pershing Square Capital Management have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARP

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top